# Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination

> **NCT01650389** · PHASE2 · COMPLETED · sponsor: **Mark Hatherill** · enrollment: 248 (actual)

## Conditions studied

- Tuberculosis
- HIV

## Interventions

- **BIOLOGICAL:** MVA85A
- **BIOLOGICAL:** Candin
- **BIOLOGICAL:** BCG Vaccine SSI

## Key facts

- **NCT ID:** NCT01650389
- **Lead sponsor:** Mark Hatherill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2015-09-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650389, "Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01650389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*